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According to the National Survey on Drug Use and Health (SAMHSA, 2012), 22.2 
million Americans were identified as substance dependent. Of those 22.2 million, 1.1 million are 
dependent on cocaine, making it the third-most widely abused illicit drug. Cocaine is a strong 
psychomotor stimulant that increases levels of dopamine (DA) within the mesocorticolimbic 
system, resulting in euphoric effects and sustained feelings of pleasure. Sustained drug use leads 
to disruptions in reward and motor centers, resulting in increases of locomotor activity, salience 
of drug-related stimuli, and dysfunction in neurotransmitter regulation (Penberthy et al., 2010; 
Hyman and Malenka 2001). Recreational use of drugs are attributed to environmental influences, 
peer-pressure and are used in an attempt to momentarily alleviate negative mood states (Koob 
2009). However, acute use fosters the development of compulsive drug use and behaviors due to 
increased hedonic values or genetic vulnerability (Koob 2000; Dong and Nestler 2014).  
Sex differences have been well documented with respect to cocaine addiction.  Although 
males are more likely to use drugs for recreational use, females are at higher risk of developing 
physiological consequences from drug use and develop a dependency on drugs at a faster rate 
and lower dose and have a higher risk of relapse (Brady and Randall, 1999; Ignjatova and 
Raleva, 2009). The difference in vulnerability may stem from dimorphic differences in gonadal 
hormones with a particular interest in estrogen. Research has shown high levels of estrogen 
facilitate the rewarding effects of cocaine and a faster preference to the cocaine-paired chamber 
(Lynch et al., 2001). Upon reaching puberty, females begin to ovulate monthly and synthesize 
estrogen during the menstrual cycle. Estrogen levels rise and peak during the follicular and 
steadily decrease in the middle of the luteal phase of the menstrual cycle (Evans and Foltin 
2010). 
Estrogen receptors are concentrated near midbrain dopamine systems such as the ventral 
tegmental area (VTA) and serotonergic systems including the raphe nuclei, implicating a critical 
role for estrogen in modulation of reward value, cognition and motor functions (Nomura et al., 
2005; Creutz and Kritzer 2002) by regulating the expression of critical enzymes in the synthesis 
of neurotransmitters (Gundlah et al., 2005). Estrogen has been implicated in increasing DA firing 
rate, fibers and striatal DA release (Becker, 1999) and the subjective effects of cocaine are 
reported as “more pleasurable” during the follicular phase, when estrogen is highest (Lukas et 
al., 1996). Upregulation of DA processes may result in a more intense vesicle release of DA or 
prolonged burst firing of DA axons. This contributes to feelings of reward when presented with a 
stimulus. 
Different pharmacological agents have been proposed as effective for cocaine addiction.  
Some treatments include methamphetamine, levo tetrahydropalmatine, GABAergic medications, 
and disulfiram. However, increasing concerns regarding efficacy and side-effects have made it 
difficult to begin implementing treatments into rehabilitation clinics. Pharmacological treatments 
offer short-term relief but become a liability for abuse and those that are have yet to have their 
mechanism determined (Shorter and Kosten, 2011). A second obstacle with current treatments is 
relapse rates for cocaine addicts is disconcerting, with nearly a quarter relapsing to cocaine 
within the first week of being discharged (DATOS, 2001; Simpson et al., 1999), signaling 
treatments have limited efficacy on short-term cognitive dysfunctions but do not treat disrupted 
neural circuitry, which persists for years after abstinence and are problematic for the continuation 
of improvement in quality of life for recovering addicts (Simpson et al., 2002). Although cocaine 
addicts often show similar neural dysfunctions and symptoms, many often suffer from 
comorbidities such as psychiatric disorders, poly substance abuse and cardiovascular problems 
(Miller and Ries, 2004; Devlin and Henry, 2008). Research into cocaine treatments must also 
take this into account, illustrating the complexity and difficulty in developing safe and efficient 
cocaine treatments.  
One of the more promising pharmacological treatments for cocaine addiction is N-
acetylcysteine (NAC). NAC is effective in inhibiting reinstatement of cocaine, cue-induced 
reactivity (Moussawi et al., 2009) and successfully reverses cocaine’s plastic effects (McClure et 
al., 2014; Reichel and See et al., 2012). NAC has been shown to restore glial GLT-1, 
normalizing extracellular glutamate levels in the nucleus accumbens and increasing activation of 
metabotropic glutamate receptor 5 (mGluR5) (Reissner et al., 2014), a receptor implicated in 
cocaine-seeking behaviors (Schmidt et al., 2013). Studies have demonstrated NAC reduces 
elevated glutamate levels (Schmaal et al., 2012) and elevated glutathione levels in astrocytes and 
reverses excitotoxicity (Badisa et al., 2015), suggesting NAC reduces increased glutamate levels 
associated with impulsivity. In response to viewing slides depicting cocaine and cocaine use, 
self-reports from hospitalized subjects given NAC for three days showed a decrease in desire to 
use and a lower response to cocaine slides (LaRowe et al., 2007). 
Taurine is an essential amino acid that displays several neuropsychopharmacological 
roles such as neuromodulator, neurotrophic, and osmomodulatory roles (Wu and Prentice, 2010). 
Humans mainly obtain taurine through their diet (Laidlaw et al., 1990). Although taurine is 
found in all foods, taurine is highest in meat and shellfish such as clams and mussels and grains 
such as beans and nuts. Taurine is also found in many energy drinks, a popular beverage 
typically consumed by adolescents and has been shown to have adverse effects on the developing 
brain and increasing the risk of future drug abuse (Reissig et al., 2009), although energy drinks 
also contain high amounts of caffeine and other stimulants (Aranda and Morlock, 2006). The 
potential health effects of these other substances have yet to be determined.  
Taurine has been shown to be effective in reducing the neurotoxicity typically induced by 
drugs of abuse such as methamphetamine and cocaine through activation of antioxidant and 
mTOR signaling pathways (Li et al., 2012; Banerjee et al., 2013). It has been found that 
following chronic cocaine infusion, taurine levels in the brain increase, suggesting taurine may 
play a neuroprotective role in reducing cell death induced by glutamate-mediated neurotoxicity 
(Yablonsky-Alter et al., 2009). Preliminary studies have shown co-administration of taurine and 
cocaine reduces cocaine-induced locomotor activity and conditioned place-preference (Banerjee 
et al., 2013). 
 The behavioral paradigm employed in the study is conditioned place preference (CPP), a 
behavioral model commonly used to assess the reinforcing properties of a stimulus in the 
absence of the stimulus itself (Prus et al., 2009). Using a three chambered apparatus, a drug or 
stimulus is paired with an outer chamber while the other outer chamber is the vehicle-paired 
chamber. The middle chamber functions as a walkway between both paired-chambers. Peripheral 
chambers are distinguished from each other by environmental cues such as rough vs smooth 
textures, grid patterns, and color schemes. By conditioning the animals to associate a particular 
context with the rewarding effects of a stimulus, the rewarding effects of the stimulus are 
extended to the environment, allowing the environment to function as a conditioned stimulus 
(Pearce and Bouton, 2001). Although both self-administration and CPP measure the rewarding 
value of a stimulus, CPP allows for testing animals in a drug-free state and testing the 
motivational effects of drugs (Bardo and Bevins, 2000) .Unlike self-administration, where rats 
must learn a task, lever-press, and a single behavior is reinforced while other behaviors are 
weakened (Panlilio and Goldberg 2007), CPP relies on the rewarding properties of a stimulus 
and the strength of its associability with environmental cues. A second critical difference 
between the two paradigms is that distinct neural mechanisms mediate the reinforcing properties 
(Corbit and Balleine, 2005), demonstrating that addiction is a complex disorder that is not fully 
explained by any one test. Therefore, by using preference as a measurement of the rewarding 
strength of the drug, CPP is a reliable indicator of the rewarding value of a stimulus and the 
animal’s ability to associate contextual cues with the rewarding stimulus. 
The objective of this study is to assess the potential of taurine as an intervention for 
substance abuse and to address if sex difference plays a role in the efficacy of taurine in reducing 
cocaine preference. Moreover, we also investigated whether gonadal hormones regulate taurine’s 
efficacy for reducing cocaine reward. 
 
Methods 
Thirty-six intact or gonadectomized (GDX) male and female Sprague-Dawley rats are 
divided into four groups (Table 1). All rats were housed in a climate-controlled facility with a 
12-h light/dark cycle with ad libitum access to food and water. Housing and care were conducted 
in accordance with 1996 Guide for the Care and Use of Laboratory Rats (Institute of Laboratory 
Animal Resources on Life Sciences, National Research Council, 1996). Pretreatment injections 
of either taurine (100 mg/kg) or saline were administered for two weeks and were injected 
intraperitoneal (IP). The volume is based on the animal’s weight, volumes ranged from .35 to .52 
mL for males and .25 to .36 mL for females.   
After two weeks of pre-treatment, a ten-day CPP behavioral paradigm was employed. 
Day 1 of behavior was for habituation. Animals were placed into the middle chamber and are 
allowed to freely explore the chamber for 15 minutes. During conditioning (day 2 through day 
9), before being placed into the CPP chamber, the animals received two injections of either 
hydrochloric cocaine (15 mg/kg), saline, or taurine and are placed into the rough texture chamber 
for 30 minutes. On alternate days, all treatment groups received two injections of saline on both 
sides of the torso and were placed into the smooth texture chamber for 30 minutes. On the tenth 
day, behavior was assessed. Animals were placed into the middle chamber with dividers in place. 
The dividers were removed and the animals were allowed to freely explore the chamber for 15 
minutes and behavior was recorded. The cohorts of male and female rats were performed at two 
different times to avoid phenomenal cues.  
 




(# of animals) 
Co-administration 





Females-Intact Taurine (n = 27) Cocaine+Taurine (n = 9) 
Cocaine+Saline (n = 9) 







 Saline (n = 9) Cocaine+Saline (n = 9) Coc+Sal Sal 
Males-Intact Taurine (n = 27) Cocaine+Taurine (n = 9) 
Cocaine+Saline (n = 9) 







 Saline (n = 9) Cocaine+Saline (n = 9) Coc+Sal Sal 
Females-OVX Taurine (n = 27) Cocaine+Taurine (n = 9) 
Cocaine+Saline (n = 9) 







 Saline (n = 9) Cocaine+Saline (n = 9) Coc+Sal Sal 
Males-GDX Taurine (n = 27) Cocaine+Taurine (n = 9) 
Cocaine+Saline (n = 9) 











 Overall, pretreatment of taurine was effective in attenuating cocaine preference in male 
and female rodents.  However, in females, its efficacy was dependent on whether taurine and 
cocaine were co-administered.  Two-way ANOVAs were used to determine how treatment 
impacted time spent in the paired and unpaired chambers.  Planned t-test comparisons were 
performed to determine significant differences between the paired and unpaired chambers within 
each treatment.  Significance was determined by a p < 0.05.   
 . The control group of intact male rats conditioned to cocaine showed a significant 
preference to the cocaine-paired chamber (Figure 1; t-value = 2.35;  p = 0.037) compared to the 
unpaired chamber. Intact males exposed to a pre-treatment of taurine and conditioned to cocaine 
show no significant preference towards either chamber. Pre-treatment of taurine and co-
administration of taurine/cocaine further reduces cocaine-preference, showing no significant 
differences between time spent in paired and unpaired chambers. . Males that were pre-treated 
with taurine and conditioned to taurine did not show a significant preference to the taurine-paired 
chamber. 
 
 Intact-females form a preference to the cocaine-paired chamber (Figure 2; t-value = 2.16;  
p = 0.05) when they are not pre-exposed to taurine. Overall, the two-way ANOVA determined 
that intact females do not form a preference to the taurine-paired chamber. Similar to intact 
males, taurine pre-treatment reduces cocaine preference in intact females, showing no significant 
difference between the time spent in the paired and unpaired chambers. Interestingly, taurine pre-
treatment and co-administration of taurine/cocaine significantly enhances cocaine preference (t-
value 2.85 = p < 0.01).  
 
 GDX-males that were not exposed to taurine form a significant preference to the cocaine-
paired chamber (Figure 3; t –value = 2.78); p=0.024). A two-way ANOVA revealed that GDX 
males pre-treated with taurine did not show any significant preference to the cocaine, 
cocaine/taurine or taurine paired chambers when compared to the preference time for the 
unpaired chambers.   
 
 Finally, and interestingly, a two-way ANOVA revealed a significant interaction in OVX-
females (Figure 4: F (3,62) = 4.11;  p < 0.01).   OVX females did not show a significant 
preference to the cocaine paired chambers under any conditions.  Interestingly, OVX females did 
establish a significant preference to the taurine-paired chamber, when pre-treated with taurine for 
two weeks (t-value = 3.20; p < 0.0064). These significant differences between the females 
conditioned to cocaine versus taurine are what are driving the significant interaction, as seen by 







Figure 1: Taurine attenuates cocaine preference in intact male rats. Males conditioned to cocaine-
only show a significant preference (*) towards the cocaine paired chamber (p<0.036). Taurine 
pre-treatment as well as taurine co-administration diminishes cocaine preference as observed 
when there are no significant differences in the time spent in the paired and unpaired chambers. 




Figure 2: Co-administration with taurine enhances cocaine preference in intact females. Pre-
treatment with taurine decreases cocaine preference; however, co-administration of taurine 
enhances preference to the drug-paired chamber in female rats (**; p<0.01). Females conditioned 
to pre-sal/coc+sal show a significant preference (*) towards the cocaine-paired chamber. Taurine 
pre-treatment attenuates cocaine-preference. Pre-tau/tau+sal group do not form a preference 













Figure 3: Cocaine preference and taurine efficacy is not testosterone-dependent. GDX males 
conditioned to cocaine-only show a significant preference (*) towards the cocaine paired 
chamber (p<0.025). GDX males do not form a preference to the taurine-paired chamber. Pre-























Figure 4: Lack of ovarian hormones results in taurine preference while cocaine preference is not 
acquired. A two-way ANOVA revealed a treatment by preference interaction (F (3,62) = 4.11;  p 
< 0.01).  OVX females do not form a preference to the cocaine-paired chamber. However, a 





















Intact males and females form a preference to the cocaine-paired chamber. Pre-treatment 
of taurine is sufficient to attenuate cocaine preference in both intact males and females. Neither 
intact male or intact female groups show a preference to the taurine-paired chamber. Taurine pre-
treatment and co-administration of taurine+cocaine further decreases cocaine preference in intact 
males but exacerbates cocaine preference in intact females. OVX females do not show a 
significant preference towards the cocaine-paired chamber but, interestingly, do show a 
preference to the taurine-paired chamber. There is an interaction in the OVX-females with 
treatment and preference . GDX males form a preference to the cocaine-paired chamber but pre-
treatment and co-administration of taurine reduces cocaine preference to non-significant levels.  
 
 
Experiment 1: Taurine pre-treatment reduces cocaine preference in intact males 
 Taurine pre-treatment is sufficient to reduce cocaine preference in males. Co-
administration of taurine during conditioning further reduces cocaine preference. Similar results 
have been seen in treatments for relapse. NAC, in addition to its effect in glutamatergic systems, 
also has been implicated in neurotrophic, antioxidant, and inflammatory pathways (Dean et al., 
2011), in virtue by acting as a glutathione precursor (Asevedo et al., 2014). Rats chronically-fed 
ethanol are found to have reduced glutathione in their plasma and tissue, resulting in oxidative 
stress and damage to cellular structure and function (Pushpakiran et al., 2004). Simultaneous 
taurine administration with ethanol was found to restore glutathione levels, suggesting that 
taurine and NAC may work through similar, but different pathways as neuroprotective molecules 
in drug-induced toxicity. 
 Previous biochemical studies done by Banerjee at al. 2013demonstrated taurine injected 
directly into the striatum reduced spontaneous locomotor activity and CPP for cocaine. Findings 
from this experiment validate these findings. Pre-treatment of taurine is sufficient to reduce 
cocaine-preference to non-significant levels and co-administration of taurine reduces it even 
further.  Studies in the same lab (Chan et al., 2014), found taurine modulates NMDA receptors 
through multiple mechanisms including reducing affinity of NMDA for glycine and through 
TAG receptors. Yablonsky-Alter et al. found that after chronically-withdrawn rats are given a 
cocaine challenge, there is an increase of glutamate release in the striatum but, concurrently, 
there is an increase of taurine. Taurine’s inhibition of NMDA may be a mechanism through 
which the effect of glutamate-induced neurotoxicity is blunted, providing a self-protection 
mechanism against cocaine addiction and excitotoxicity. 
 
Experiment 2: GDX males show the same response to taurine as intact males 
 GDX males show the same development of preferences as intact males. GDX males form 
a preference towards the cocaine-paired chamber (p<.03) but pre-treatment and co-treatment of 
taurine reduces cocaine’s rewarding effect. Acute or chronic exogenous administration of 
testosterone did not differ in time spent in the cocaine-paired chamber when compared to GDX 
males. The finding that GDX males show similar results as intact males (Minerly et al., 2008), 
suggests testosterone offers minimum contribution to the rewarding effects of cocaine or taurine. 
In terms of locomotion, GDX males did show a transient increase in locomotion, but did not 
show a progressive increase of locomotion in response to cocaine sensitization (Menendez-
Delmestre and Segarra 2011) when compared to intact. However, the GDX+ testosterone 
replacement group did show sensitization to cocaine but this effect has not been consistently 
found as other studies found testosterone treatment in castrated males does not cause behavioral 
sensitization (Forgie and Stewart 1994). In addition, testosterone does not regulate the 
dopaminergic release in either the striatum or nucleus accumbens (Becker 2009; Triemstra et al., 
2008), suggesting that unlike estrogen, testosterone does not confer any biochemical facilitatory 
effects. 
 
Experiment 3: Taurine pre-treatment and co-administration potentiates cocaine preference in 
intact females 
In intact females, pre-treatment of taurine is sufficient in reducing cocaine preference. In 
the brain, taurine functions as a neurotransmitter and may modulate cocaine’s rewarding effect. 
Taurine supplementation has been shown to be effective in reversing and treating the deleterious 
physiological effects of chronic ethanol consumption (Chen et al., 2009; Park et al., 2009). 
Acamprosate, a glutamatergic neuromodulator, has been recently investigated as a potential 
treatment for cocaine addiction. Similar to taurine, acamprosate was first touted as an 
intervention treatment for reducing ethanol consumption and ethanol-drinking behavior (Oka et 
al., 2013). Recently, acamprosate has been investigated as a potential treatment for cocaine 
dependence and reinstatement. Acamprosate inhibited reinstatement of both cocaine-preference 
(Mcgeehan and Olive 2006) and self-administration (Bowers et al., 2007). Although its exact 
mechanisms remain unknown, similar mechanisms that mediate the efficacy of acamprosate 
mediate the effects of taurine through the glutamatergic system (Boothby and Doering 2005). 
mGluR5 has been implicated in the compulsive behaviors associated with alcohol (Blednov and 
Harris 2008) and cocaine dependence (Reissner et al., 2014), making it an ideal candidate for 
drug treatments. Interactions between mGluR5 and estrogen have been shown to facilitate of 
cocaine’s rewarding (Peterson et al., 2014) and motor sensitization (Grove-Strawser et al., 2010), 
suggesting the receptor may be the driving force between the dimorphic difference in drug 
escalation and addiction rates between males and females. Taurine pre-treatment may be 
inhibiting the activation of mGluR5 by decreasing calcium-evoked currents (Albinana et al., 
2010) or the binding of estrogen to the receptor.  
However, co-administration of taurine exacerbates cocaine preference in intact females. 
The intensification of preference may be due to the presence of gonadal hormones, specifically 
estradiol. Estradiol has been shown to facilitate the rewarding effects of drugs of abuse such as 
cocaine and methamphetamine and may be responsible for the increased vulnerability female’s 
display to drugs of abuse. Bobzean et al., (2014) showed that acute estradiol injections in OVX 
female rats prior to test for CPP produced a significant preference for the cocaine-paired 
chamber, demonstrating a prominent role for estradiol in enhancing cocaine preference. Cocaine 
has also been shown to induce increases of estradiol and testosterone in intact females but not 




Experiment 4: OVX females form a preference to the taurine-paired chamber 
OVX females do not show a preference to the cocaine-paired chamber. This may be due 
to the lack of estrogen present in the body. Van Swearingen et al. (2013) showed that OVX 
female rats given a 30mg/kg challenge dose of cocaine do not develop a preference to the 
cocaine-paired chamber but when given estradiol replacement injection and then a challenge 
dose, a preference is formed. This emergence of preference after estrogen treatment shows that 
that the presence of estrogen is required for the formation of cocaine-preference. Bobzean et al. 
(2014) has shown OVX females develop preference for the cocaine-paired chamber at 5mg/kg 
and 10 mg/kg cocaine doses but not at 2.5 mg/kg and 15 mg/kg despite no difference in 
locomotor activity in the treatment groups. This demonstrates a dose-response curve in OVX-
females to cocaine. Moderate doses create a preference but low or high doses may produce 
aversive properties to the chamber or may too low a dose to create a substantial rewarding effect 
or satiates any cravings in the rats.   
The most interesting result is that OVX females form a preference to the taurine-paired 
chamber since intact females did not form a preference to the taurine-paired chamber. Loss of 
estrogen in females may occur due to surgery or natural cause. Limited studies have shown pre-
mature loss of estrogen is accompanied by cognitive defect, primarily in the verbal episodic 
memory but there has not been enough studies to substantiate these conclusions (Henderson and 
Sherwin, 2007; Henderson 2007). What is true for both conditions is loss of estrogen results in 
an increase in anxiety, cognitive defects, and increases in dementia (Brann et al., 2007). The 
natural loss of estrogen occurs when women reach menopause, where estrogen levels begin to 
decline, resulting in cognitive defects in memory and learning. Taurine may play a role in 
reducing the anxiety associated with the decline in estrogen. Furuta et al., (2013) found that 3 
week postpartum primiparous rats spent the least time in the open arms of the elevated plus maze 
and highest immobility time during the forced swim test. When given estradiol (E2) injections 
daily for 6 days, E2 significantly reduced anxiety and depressant actions in the elevated plus 
maze and forced swim tests. In addition, administration of E2 directly to the hippocampus and 
amygdala decreased anxious and depressive behaviors (Walf and Frye, 2006). This may suggest 
that while the presence of estrogen potentiates cocaine’s rewarding effect, its absence creates 
negative mood states (Pandaranandaka et al., 2009).  
Whirley and Einat (2008) found that taurine administration was not effective in reducing 
anxiety and depressive behaviors in mice. However, this disparity may be explained because of 
the anxiety phenotypes the mice showcased. McCool and Chappell (2007) initially found 
strychnine, a glycine antagonist, reduced anxiety in the elevated plus maze and light/dark box 
while taurine’s anxiolytic effect was negligible in intact rats. However, when separated into 
“low” anxiety and “high” anxiety groups, taurine showed a significant effect in increasing time 
spent in the open arms in “high” anxiety animals, representing a reduction in anxiety. This effect 
illustrates that taurine is effective in reducing anxiety in highly anxious animals but not as 
effective in low anxiety animals. In accordance with our findings, pre-treatment and co-
administration of taurine reduces preference to cocaine, a psychostimulant known to induce high 
levels of anxiety (Paine et al., 2002). OVX females, a high anxiety phenotype, do form a 
preference to the taurine-paired chamber but intact females do not. Furthermore, taurine has been 
shown to be effective as an anti-depressant in diabetic rats, a population known to be at higher 
risk for depression (Caletti et al., 2012; Toyoda and Lio, 2013). Studies performed in our lab 




The subjective feelings associated with psychostimulants changes with the phases of the 
menstrual cycle but with other classes of drugs, this effect is moderate. Taurine may be an 
effective prevention model for cocaine but may not be as effective in preventing addiction from 
sedatives, ethanol, prescription drugs and benzodiazepines because estrogen has been found to 
not alter the physiological and subjective effects of other classes of drugs except for 
psychostimulants (Terner and Wit, 2006). Taurine’s preventive effect may only be effective in 
drugs that work through DA and its mechanisms such as blocking its reuptake or reversing the 
flow through the dopamine transporter (DAT). Terner and Wit also believe estrogen modulates 
the subjective effect of psychostimulants because this class of drug has direct actions on DA 
processes, while other classes of drugs indirectly alter the DA mechanism. Although many 
studies inject exogenous estrogen to portray the rise in estradiol seen in women entering the 
follicular phase of the menstrual cycle or in rats entering the diestrus cycle (Caligioni 2009; 
Owen Jr., 1975), gonadectomy also excludes other important hormones such as follicle 
stimulating hormone, luteinizing hormone, progesterone, and testosterone. There is limited 
literature investigating the role of other gonadal hormones which are important in regulating the 
normal human physiology and may impact cocaine pharmakinetics and treatment options.  
While CPP is a useful tool in measuring reward value, the model does have several 
limitations. A concern with CPP is that it involves a cognitive component. CPP evaluates 
preferences based of associations animals make between context and the reward (Dixon et al., 
2013). Therefore, it measures an animal’s overall experience with an environment and does not 
address an animal’s specific behavioral and physiological response to a drug. CPP is a behavioral 
paradigm designed to assess the reward value of a drug by time spent in the paired-chamber and 
does not tell us about the reinforcement of a drug.  
The behavioral paradigm, self-administration, more closely mimics the human drug 
addiction with drugs being immediately administered and better models the compulsive nature of 
cocaine addiction (Panlilio and Goldberg) than CPP. Self-administration is a model designed to 
reinforce responses through the effects of drugs, leading to behavioral sensitization, a crucial 
aspect of addiction seen in the natural world. Self-administration can also be better used to test 
drug treatments and produces a more valid predictor of clinical efficacy (O’Connor et al., 2011).  
 
 
 Possible Mechanisms by which Taurine can inhibit cocaine preference 
Previous research on taurine has elucidated taurine’s role in physiological and cellular 
functions (Schaffer et al., 2010; Hussy et al., 2001) but never in the context of a reward. This 
study is the first to test if taurine can act as a rewarding stimulus. Therefore, a pre-tau/tau+sal 
group is included to investigate if reductions of cocaine preference are due to the neuroprotective 
role of taurine and not because of a competing stimulus. In both intact males and females and 
GDX-males, there is no significant preference to the taurine-paired chamber, showing taurine is 
not a rewarding stimulus and reductions of cocaine-preference is due to taurine’s 
neuromodulatory effects. Therefore, decline of preference in the pre-tau/coc+sal suggests taurine 
reduces cocaine’s rewarding effect.  
One mechanism through which taurine may reduce cocaine preference is reduction of 
stress. Females have also been found to higher levels of corticotrophin-releasing factor receptors, 
the main stress hormone, suggesting a higher risk for the effects of stress such as cardiovascular 
disease, anxiety, depression, and substance abuse (Bangasser et al., 2010; Valentino et al., 2013). 
Deviations from normal corticosteroid levels may produce anxiolytic-like symptoms and 
discomfort (McEwen 2007), pushing individuals to self-medicate. Taurine has been implicated in 
combining with antioxidants to create a more stable antioxidant to suppress the inflammatory 
effects of cytokines (Wojcik et al., 2010). Activation of the hypothalamic-pituitary-adrenal axis 
(HPA) axis during bouts of stress release glucocorticoids and catecholamines that suppress the 
action of cytokines (Elenkov and Chrousos 2002). During self-administration, plasma 
corticosterone levels follow a dose-related curve (Goeders et al., 1998). Cocaine induces anxiety 
and panic in humans and animals (Goeders, 2002). It may be taurine reduces the strength of the 
negative reinforcement motivation (Koob et al., 2014) or suppress the impact of cytokines (Park 
et al., 2009), decreasing the need to alleviate the distress and craving to self-medicate. This 
implicates taurine as being a potential treatment for preventing cue-induced drug seeking 
behavior, a major cause for recovering addicts to relapse. 
Taurine is also a structural analog of GABA and glycine, suggesting that its 
neuroprotective role may stem from its activation of GABA and glycine receptors (Horikoshi et 
al., 1988). Chronic high-dose of cocaine induces long term potentiation (LTP) in ventral 
tegmental area (VTA) neurons and disinhibits VTA DA neurons through inhibition of GABA-
voltage-sensitive sodium channels (Liu et al., 2005; Steffensen et al., 2008), enhancing 
mesocorticolimbic DA transmission. It is possible midbrain GABA neurons modulate the 
hedonic value and salience of cocaine and other drugs of abuse. In disregulated systems, drug-
seeking behavior and reward value are reinforced, resulting in drug abuse and addiction. 
Albinana et al., found acute application of taurine induces a dose-dependent chloride 
conductance through GABAA channels and regulates calcium conductance. Medium and high 
concentrations of taurine bind to glycine and GABA receptors, respectively, in the basolateral 
amygdala, hippocampus, and nucleus accumbens (Jia et al., 2008) as well as inhibit thalamic 
relay neurons. Taurine is also transported by the GABA transporter at the blood brain barrier as 
well as by its own transporter, (Takanaga et al., 2001), illustrating the importance of taurine in 
the CNS. Albinana also found intracellular dialysis of GDP-β-σ inhibited the reduction of 
calcium conductance seen by taurine binding, demonstrating taurine modulation on voltage-
gated calcium channels is mediated by G-protein coupled receptors (GPCR). This mechanism is 
poorly understood and future research may be directed to investigate if similar GPCR’s are found 
in the rat and human brain.  
Current research has been investigating the role of taurine and NMDA receptors and their 
role in cocaine addiction. Chan et al., (2014) showed that taurine does interact with NMDA 
receptors through multiple mechanisms. Continuing down this avenue, Chan et al., (2015) 
elucidated that taurine modulates NMDA activation through interactions with the 
GluN1/GluN2B subunit. Blocking of GluN2B NMDA receptors rescued dysfunctional long-term 
depression in the oval bed nucleus of the stria terminalis, suggesting an important role of NMDA 
receptors in the metaplasticity evoked by cocaine and relapse (deBacker et al., 2015). Since, 
taurine inhibits NMDA through GluN2B and GluN2B has been shown to be critical for addiction 
and relapse (Yuan et al., 2013) and glutamate has been implicated as the mediator of cocaine-
induced reinstatement and relapsing (Cornish and Kalivas, 2000), taurine is a potential candidate 
for treatment for substance abuse disorders.  
 
Implications 
 Taken together, the data suggests taurine is an effective intervention for substance use 
disorders but its efficacy is dependent on hormonal status. Taurine’s efficacy is not contingent on 
the presence of testosterone as intact and castrated males show similar results. Dimorphic 
differences to cocaine and taurine may be due to differing levels of estrogen. Estrogen enhances 
NMDA excitatory post synaptic potentials (EPSPs) (Foy et al., 1999) and LTP (Smith and 
McMahon 2006). Acute cocaine has been found to increases mesocorticolimbic spine density 
and excitatory synapses (Luscher and Malenka 2011), an attribute shared with estrogen 
(Srivastava et al., 2008). Cocaine produces hyperactivation of PFC-NAc efferents, leading to 
increased salience of drug-associated cues and occurrence of compulsive behaviors and cocaine 
use fosters ΔFosB accumulation, resulting in the potentiation of synaptic NMDA insertion in 
NAc neurons (Dong and Nestler), a critical reward structure. Taurine pre-treatment inhibits 
GluN1/GluN2B subunit, reducing NMDA excitation and decreasing cocaine reward and 
preference. However, crossing a certain threshold of taurine levels may reverse its protective 
effect and facilitate cocaine’s rewarding effect. 
Addiction is a disorder of cognition and behavior and involves the interplay of several 
disrupted brain structures and functions. When cocaine-preference is brought to extinction and a 
challenge dose is administered, rats still show a significant preference towards cocaine 
(Brenhouse and Andersen 2008), demonstrating the presence of disrupted neurocircuitry even 
after prolonged, suggesting treatment for drug addicts is a complex process. Progesterone and 
exercise have been shown to be effective in reducing the reinstatement of cocaine preference but 
this effect is greater in females than males (Zlebnik et al., 2014), indicating the importance of 
taking into account and investigating the impact sex differences have on the effectiveness of drug 
abuse treatments. Rehabilitation clinics should implement multimodal treatment programs to 
address the global disruptions caused by drug abuse. By implementing multimodal programs, 
treatments are able to treat drug abuse from multiple facets, treating the myriad of familial, 
biological and maladjusted social behaviors associated with drug abuse and tailor specific 
treatments for patients.   These studies support that taurine is a viable candidate for cocaine 
addiction, with potentially few side effects, and, in addition, could be neuroprotective. Further 
studies need to be performed to assess how taurine is acting on the mesocorticolimbic circuit to 
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